Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Recruiting 36Active not recruiting 23Completed 18Terminated 10Withdrawn 5Not yet recruiting 5Unknown 3Approved for marketing 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 5Carcinoma, Pancreatic Ductal 1Carcinoma 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × abemaciclib × Clear all
NCT07428018 2026-03-05

VIOLET

Mario Negri Institute for Pharmacological Research

Phase 2 Not yet recruiting
150 enrolled
Breast

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Fudan University

Phase 2 Not yet recruiting
189 enrolled
Breast

Breast Neoplasms

NCT07292207 2025-12-18

ARCHE

Nagoya City University

Phase 2 Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Hubei Cancer Hospital

Phase NA Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Fudan University

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡